China-based vaccine makers CanSino Biologics (HKG: 6185) and Livzon Pharmaceutical Group Inc. (HKG: 1513) have received emergency use authorizations (EUAs) from Chinese regulators for their respective COVID-19 vaccines as sequential booster shots. The approvals expand the country’s arsenal of heterologous boosters amid rising demand for enhanced protection.
CanSino’s Inhaled Vaccine
CanSino’s recombinant coronavirus vaccine, an inhaled adenovirus type 5 vector product, received clinical trial approval in March 2021. The vaccine stimulates humoral, cellular, and mucosal immunity, offering triple protection without intramuscular injection. The EUA positions it as a needle-free booster option for widespread use.
Livzon’s V-01 Vaccine
Livzon’s V-01, a recombinant protein vaccine co-developed with the Chinese Academy of Sciences, completed Phase III trials meeting pre-set endpoints. Data show V-01 as a heterologous booster offers strong safety, immunogenicity, and prolonged neutralizing antibody titers. The EUA clears its use as a sequential booster in China’s vaccination strategy.
Strategic Implications
The approvals reflect China’s push to diversify booster options beyond traditional mRNA and inactivated vaccines. CanSino’s inhaled platform and Livzon’s protein-based vaccine address varying needs, from ease of administration to long-term efficacy. Both firms are poised to supply boosters domestically and explore global markets.-Fineline Info & Tech
